Oleclumab
Oleclumab
Oleclumab (pronunciation: oh-leh-kloo-mab) is a monoclonal antibody designed for the treatment of various autoimmune diseases and cancers.
Etymology
The name "Oleclumab" is derived from the International Nonproprietary Names (INN), where "Ole-" refers to the human origin, "-clu-" is the target class stem for immunomodulating agents, and "-mab" is the stem for monoclonal antibodies.
Function
Oleclumab works by binding to the CD73 molecule, an enzyme found on the surface of many types of cells. This binding inhibits the function of CD73, which plays a crucial role in the progression of certain diseases. By blocking CD73, Oleclumab can help to slow down or stop the progression of these diseases.
Clinical Trials
Oleclumab has been studied in several clinical trials for its potential use in treating various conditions. These include rheumatoid arthritis, multiple sclerosis, and certain types of cancer.
Related Terms
- Monoclonal Antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Autoimmune Disease: An illness that occurs when the body tissues are attacked by its own immune system.
- Cancer: A group of diseases characterized by the uncontrolled growth and spread of abnormal cells.
- CD73: An enzyme that plays a crucial role in the progression of certain diseases.
- Clinical Trials: Research studies that test how well new medical approaches work in people.
External links
- Medical encyclopedia article on Oleclumab
- Wikipedia's article - Oleclumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski